Ampio Pharmaceuticals, Inc. (AMPE)


NYSE MKT - NYSE MKT Real Time Price. Currency in USD
0.76+0.00 (+0.37%)
As of 3:20 PM EDT. Market open.
People also watch:
ACRXMRNSANTHALIMAVEO
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open0.78
Prev Close0.76
Bid0.77 x 100
Ask0.77 x 1700
Day's Range0.76 - 0.79
52wk Range0.75 - 4.32
1y Target EstN/A
Market Cap43.49M
P/E Ratio (ttm)-1.36
Beta0.17
Volume182,164
Avg Vol (3m)857,756
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • PR Newswireyesterday

    Ampio Updates Clinical and Regulatory Activity

    ENGLEWOOD, Colo., Sept. 29, 2016 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) announced the Company has met with the CBER Division of the FDA to seek guidance on the best path forward to obtain a Biological License for Ampion™ to treat patients suffering from pain caused by severe osteoarthritis of the knee (OAK). Michael Macaluso, Ampio's CEO noted, "We are grateful to CBER for their thorough review of our data, which referenced over 1800 patients across multiple trials. CBER's guidance included a number of very good options and as a result, we are continuing discussions.

  • PR Newswire22 days ago

    Ampio Reports Peer-Reviewed Publication on the Potential use of Ampion™ in New Clinical Indications

    Dr. David Bar-Or, Ampio's Chief Scientific Officer, explained: "We reported an important positive effect of Ampion™ on stabilization of alpha tubulin (a cytoskeleton protein involved in trafficking molecules inside the cell and important in controlling vascular permeability) in retinal endothelial cells and described the mechanism of action of Ampion™ and a resulting decrease in leakage of fluid through these cells which normally line the interior of blood vessels in the retina.

  • PR Newswirelast month

    Ampio Reports Additional Peer-Reviewed Publication on Ampion™

    ENGLEWOOD, Colo., Aug. 30, 2016 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) announced today publication in the peer-reviewed journal Biochemistry and Biophysics Reports that further describes the modes of action (MOA) of Ampion™ in the treatment of Osteoarthritis. Dr. David Bar-Or, Ampio's Chief Science Officer, noted, "This manuscript reports that in the presence of either IL-1β or TNFα, LMWF-5A (Ampion™) increased the expression of both COX2 mRNA and protein, and this increase was significant compared to that observed with IL-1β- or TNFα-stimulated, saline-treated cells.